Royal United Hospitals Bath Launches Clinical Trial Testing Repurposed Drugs for Lacunar Stroke Prevention
核心洞察
Royal United Hospitals Bath (搜索) is recruiting volunteers for a clinical trial testing isosorbide mononitrate and cilostazol to prevent recurrent strokes and cognitive decline in lacunar stroke (搜索) patients.
The 18-month study targets patients aged 30 and above who have experienced lacunar ischemic strokes caused by small vessel disease (搜索), a condition with no current treatments.
Both oral medications are being repurposed from other therapeutic areas to address the unmet medical need in small vessel disease (搜索) stroke prevention.
Royal United Hospitals Bath (搜索) (RUH Bath) has launched a clinical trial recruitment drive to test two repurposed oral medications for preventing recurrent strokes and cognitive decline in patients with lacunar stroke (搜索) caused by small vessel disease (搜索). The study will evaluate isosorbide mononitrate and cilostazol, both currently used for other medical conditions, in addressing an area with no existing treatments.
Trial Design and Patient Population
The 18-month study is recruiting patients aged 30 and above who have experienced lacunar ischemic strokes involving small blood vessels and do not have other active neurological diseases. Participants will undergo initial assessment followed by progress monitoring through phone calls throughout the study period.
Lacunar strokes occur when blockages cut off blood supply to parts of the brain through small vessel disease (搜索). According to Hayley Stoney, RUH Stroke Research Nurse, "A lacunar stroke (搜索) is quite common, but can still have very serious consequences for people, particularly the way it can affect people's thinking, balance and walking."
Addressing Unmet Medical Need
The trial addresses a significant gap in stroke treatment, as RUH Bath reports there are currently no treatments available for small vessel disease (搜索). The researchers are repurposing two existing medications that are already approved for other therapeutic indications to explore their potential in stroke prevention.
"We're really proud to be part of such an important study which has the potential to make a real difference to the quality of life of people who have already had a stroke, and others in the future too," Stoney said.
Clinical Significance
The study focuses on preventing both stroke recurrence and the associated cognitive impacts that can significantly affect patients' quality of life. Stoney emphasized the potential impact of the research, stating the study has the potential "to make a real difference" to people's "quality of life."
The research team is actively seeking volunteers, with Stoney appealing to eligible patients: "I would appeal to anyone who could be part of the trial to get in touch and find out more – you will be playing a vital role in shaping the future of treatment for stroke patients."